Mohammad Alsharabati, MD
Neuromuscular Medicine · Palos Heights, ILNPI 1174748180
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,053 of the $6,533 with a category attached, or 62.0%. 35 manufacturers reported payments, led by CSL Behring at 24.3% of the total. Reporting peaked in 2020 at $2,523 and has fallen 59.8% since, to $1,015 in 2025.
Across 196 payments — averaging $33.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2K
- AstraZeneca$1K
- AbbVie$943
- Supernus Pharmaceuticals, Inc.$257
- Lundbeck LLC$248
- Johnson & Johnson$217
- plus $2K from 29 others
What the payments were for
- Consulting fees$84013%
- Speaking & faculty fees$1,40021%
- Food & beverage$4,05362%
- Education$2414%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 12 | $1,590 |
| AstraZeneca | 8 | $1,396 |
| AbbVie(2 entities) | 70 | $943 |
| Supernus Pharmaceuticals, Inc. | 21 | $257 |
| Lundbeck LLC | 2 | $248 |
| Johnson & Johnson(2 entities) | 7 | $217 |
| Teva Pharmaceuticals USA, Inc. | 9 | $214 |
| Lilly USA, LLC | 9 | $203 |
| Genentech USA, Inc. | 3 | $135 |
| Eisai Inc. | 1 | $122 |
| Akcea Therapeutics, Inc. | 1 | $108 |
| Novartis | 6 | $107 |
| Biogen | 4 | $103 |
| Tanabe Pharma America, Inc. | 6 | $95 |
| UCB, Inc. | 3 | $95 |
| Catalyst Pharmaceuticals, Inc. | 4 | $75 |
| Argenx US, Inc. | 3 | $72 |
| Amgen | 4 | $62 |
| Alnylam Pharmaceuticals Inc. | 1 | $53 |
| Biohaven Pharmaceuticals, Inc. | 3 | $50 |
| Upsher-smith Laboratories LLC | 3 | $49 |
| Sanofi | 1 | $46 |
| EMD Serono, Inc. | 1 | $41 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Pfizer | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Impel Pharmaceuticals LLC | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| GRT US Holding, Inc. | 1 | $16 |
| Aucta Pharmaceuticals, Inc. | 1 | $15 |
| Strongbridge US Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,533 in reported general payments places this provider in the 60th percentile of 21 neuromuscular medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 22 | $1,578,676 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 120 | $1,414,562 |
| FirdapseAmifampridine Phosphate | 24 | $1,372,017 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 121 | $1,241,580 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 106 | $1,168,087 |
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 20 | $743,903 |
| SolirisEculizumab | 13 | $667,564 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 41 | $516,539 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 28 | $154,747 |
| Emgality PenGalcanezumab-Gnlm | 72 | $57,496 |
| Aimovig AutoinjectorErenumab-Aooe | 56 | $48,615 |
| Nurtec OdtRimegepant Sulfate | 30 | $34,246 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 38 | $33,861 |
| QuliptaAtogepant | 30 | $30,930 |
| Topiramate ErTopiramate | 34 | $27,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart, Vyvgart Hytrulo | $72 | $2,322,57942 claims |
| Catalyst Pharmaceuticals, Inc.Firdapse | $75 | $1,372,01724 claims |
| CSL BehringPrivigen | $1,590 | $1,241,580121 claims |
| AstraZenecaSoliris | $1,396 | $667,56413 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $11 | $34,871269 claims |
| PfizerNurtec Odt | $30 | $34,24630 claims |
| AbbVieQulipta | $943 | $30,93030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 21 neuromuscular medicine providers in Illinois.
Other neuromuscular medicine in Palos Heights
- Raghav GovindarajanO Fallon$871K
- Abigail SchwaedeChicago$73K
- Arjun SethChicago$72K
- Erik PioroChicago$45K
- Senda Ajroud DrissChicago$23K
- Robert KalbChicago$22K
- Matthew BaerElgin$15K
- Daniela MenichellaChicago$11K
- Robert SufitChicago$4K
- Richard HarveyChicago$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.